# Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years

> **NCT00788151** · PHASE2 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 300 (actual)

## Conditions studied

- Dengue Virus
- Dengue Fever
- Dengue Hemorrhagic Fever
- Dengue Diseases

## Interventions

- **BIOLOGICAL:** CYD Dengue Vaccine Serotypes 1, 2, 3, and 4
- **BIOLOGICAL:** Pneumococcal polysaccharide vaccine

## Key facts

- **NCT ID:** NCT00788151
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09-26
- **Primary completion:** 2010-02-16
- **Final completion:** 2010-08-16
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2022-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00788151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00788151, "Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00788151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*